Anesthesia

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023

Retrieved on: 
Thursday, November 9, 2023
Adjustment, TK, FDA, Genetic counseling, Nebula Genomics, Research, Sale, Genomics, Endoscopy, CDX, FDM, Food, Genetic, Heart, Therapy, Hospital Insurance and Diagnostic Services Act, COVID-19 testing, Three Months, History, Public expenditure, Omicron, Diagnosis, EBITDA, Corporation, Absorption, Genetics, Exercise, Prophase, House, Whole genome sequencing, Internet, Health Resources and Services Administration, COVID-19, Medicine, Marketing, Stella, WGS, CPT, Current Procedural Terminology, Patient, Anesthesia, Automation, Antibiotics, Renewable energy, Mobile phone, Clothing, Life insurance, Security (finance), Fine chemical, Birth control, Auction, Broadcasting, Pharmaceutical industry, Cryptocurrency, Bosc

Garden City, NY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three and nine months ended September 30, 2023.

Key Points: 
  • Three Months Ended September 30, 2023 as compared to the Three Months Ended September 30, 2022.
  • Net revenue for the three months ended September 30, 2023 was $8.4 million as compared to $24.2 million for the three months ended September 30, 2022.
  • Diagnostic services costs for the three months ended September 30, 2023 were $0.1 million compared to $2.4 million for the three months ended September 30, 2022.
  • Adjusted EBITDA loss for the three months ended September 30, 2023 was $(2.5) million compared to adjusted EBITDA income of $6.3 million for the three months ended September 30, 2023.

Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs R&D Partnership Agreement for Development of GLP1 Supplement for Pets

Retrieved on: 
Wednesday, November 8, 2023
Faculty, NYSE, São Paulo, Federal University of Rio Grande do Sul, Obesity, Cat, Université de Montréal Faculty of Veterinary Medicine, Pet, Doctor of Philosophy, Rio, UNESP, APH, Veterinary medicine, MOU, Medical school, Faculty of Medicine, University of Colombo, University of São Paulo, UFRGS, Animal, University, Universidad, Overweight, Better Choice Parking, Pain management, GLP1, Dog, MS, Physiology, Medicine, Pharmacology, Anesthesia

TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.

Key Points: 
  • TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.
  • The MOU sets out the basis for Dr. Crosignani to commence research and development of a GLP1 supplement for use in companion animals.
  • In addition, Dr. Crosignani has a post-doctorate degree from UNESP, Faculty of Medicine, researching in the field of pain management.
  • We see the use of the GLP1 supplement as a significant opportunity for the pet health industry and are assembling top tier partners to help Better Choice and our brands, including Halo, become pioneers in this sector,” commented Mike Young, Chairman of the Board for Better Choice.

Park Royal Hospital Offers Inpatient & Outpatient Electroconvulsive Therapy

Retrieved on: 
Tuesday, November 7, 2023
The American Journal of Psychiatry, Patient, Suicide, Education, The Lancet, Psychiatry, Electricity, Fear, Electroconvulsive therapy, Risk, Suicidal ideation, ECT, Brain, Depression, Safety, American Journal, Anesthesia, Death, Mental health, Pharmaceutical industry

FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.

Key Points: 
  • FORT MYERS, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Park Royal Hospital, a premier provider of mental health and addiction treatment, is pleased to offer electroconvulsive therapy (ECT) for patients.
  • At Park Royal Hospital, ECT is available on an inpatient and outpatient basis and is delivered by a trained team of professionals.
  • Electroconvulsive therapy involves using a mild electrical current to stimulate the brain to produce a brief seizure while the patient is under general anesthesia.
  • Those who are interested in receiving ECT at Park Royal Hospital do not need a referral to inquire about treatment and can begin the admissions process anytime.

EQS-News: Drägerwerk AG & Co. KGaA: Dräger significantly increases net sales and earnings in the first nine months of 2023

Retrieved on: 
Tuesday, November 7, 2023
Growth, Federal Executive Boards, Tax, EBIT, EUR, Anesthesia, Lithium

“During the first nine months of the current fiscal year, we significantly increased our net sales and earnings.

Key Points: 
  • “During the first nine months of the current fiscal year, we significantly increased our net sales and earnings.
  • Earnings development in the first nine months of 2023 was positively impacted in particular by the high net sales growth and improved gross margin.
  • Earnings after taxes also improved significantly to EUR 47.1 million (9 months 2022: EUR -112.7 million).
  • Dräger's net sales increased by 12.6 percent (net of currency effects) to EUR 788.5 million (Q3 2022: EUR 724.6 million).

Philips and County Durham and Darlington NHS Foundation Trust collaborate on a sustainability blueprint to reduce carbon emissions and waste

Retrieved on: 
Thursday, November 2, 2023
AEX, NYSE, PHG, Philips, Physician, Nursing care plan, Carbon, Darlington Memorial Hospital, Carbon footprint, Helium, Environment, NHS, County Durham and Darlington NHS Foundation Trust, Critical Care Medicine (journal), Trust, COCIR, Partnership, Design, CO2, Champalimaud Foundation, Nursing, Patient, Consultant, Ingenia, Health, Vanderbilt University Medical Center, Climate change, ICU, Anesthesia

The program identified key opportunities to reduce the carbon footprint and waste material within the intensive care unit (ICU) at Darlington Memorial Hospital.

Key Points: 
  • The program identified key opportunities to reduce the carbon footprint and waste material within the intensive care unit (ICU) at Darlington Memorial Hospital.
  • “Philips took time to undertake quantitative analysis which validated our suspicions and provided outputs we could present back to the wider Trust.
  • The analysis, developed as part of the existing 14-year strategic agreement between Philips and the Trust, supports its aims to become a leading example for environmental sustainability in human healthcare.
  • This first of kind partnership between Philips and County Durham and Darlington NHS Foundation Trust is an important milestone in the race to reach net zero and provide more sustainable care.

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

Retrieved on: 
Tuesday, October 31, 2023
Combination, Patent, Chronic pain, TEL, IP Australia, Legislation, Pain, Market, Route of administration, Opioid, Disorder, Intrathecal administration, Patient, Central nervous system, Pharmaceutical industry, Anesthesia

The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.
  • The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected to drive market growth.
  • At the same time, opioid abuse and addiction has been a global growing epidemic for more than a decade.
  • "The fact that SciSparc's number of granted patents continues to grow is proof recognizing the innovation that characterizes the technologies in the Company's pipeline.

US Anesthesia Drugs and Devices Market Set to Reach $6.83 Billion in 2023, Driven by Growing Healthcare Expenditure - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Pharmaceutical, Health, Medical Devices, Patient, Headache, Ageing, Anesthesiology, Pain, KKR, Vomiting, Abdominal ultrasonography, Somnolence, Prevalence, AstraZeneca, Conditional sentence, Lidocaine, Anesthetic, Shivering, MAC, Envision Healthcare, Nausea, 3M, Abbott Laboratories, General Electric Company, SunMed BRT station, Growth, Fungal infection, TeamHealth, COVID-19, Inhalation, Risk, AbbVie, Device, Benzocaine, Consciousness, Becton, Dickinson and Company headquarters, Blackstone, Braun, Baxter International, Ventilation, Central nervous system, ICU Medical, ICU, Pharmaceutical industry, Dentistry, Bupivacaine, Prilocaine, Anesthesia, Ropivacaine

The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices.

Key Points: 
  • The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices.
  • Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region.
  • In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia.
  • The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment.

NAPA Remains #1 for Anesthesia Management Services in 2023 Black Book Survey

Retrieved on: 
Monday, November 6, 2023
Malcolm Baldrige National Quality Award, Education, NAPA, Black Book, HITRUST, National Quality Forum, ARA, Society, Joint Commission, Patient safety organization, Becker's Hospital Review, Health, Becker, Nursing, MD, Anesthesia

MELVILLE, N.Y., Nov. 6, 2023 /PRNewswire/ -- North American Partners in Anesthesia (NAPA) is honored to announce our seventh consecutive year as the nation's highest-ranked vendor for Anesthesia Management Services, as reported by the independent Black Book Market Research. The Black Book survey results are determined by over 800,000 independent ballots from healthcare professionals and clinicians nationwide, representing over 117,000 healthcare institutions. Black Book has been recognized as a Top 25 international market research niche firm for more than 20 years, with a focus on technology, healthcare, pharmaceutical, procurement, higher education, finance, and business services.

Key Points: 
  • MELVILLE, N.Y., Nov. 6, 2023 /PRNewswire/ -- North American Partners in Anesthesia (NAPA) is honored to announce our seventh consecutive year as the nation's highest-ranked vendor for Anesthesia Management Services, as reported by the independent Black Book Market Research.
  • The Black Book survey results are determined by over 800,000 independent ballots from healthcare professionals and clinicians nationwide, representing over 117,000 healthcare institutions.
  • Even in a dynamic and difficult healthcare market, NAPA consistently proves its ability to deliver trusted, stable, and high-quality patient-centered anesthesia services."
  • This year, the ARA program also received the 2023 Patient Safety Award from the American Society of Health Care Risk Management (ASHRM).

AANA and APNA Issue Joint Statement on Ketamine Infusion Therapy for Psychiatric Disorders

Retrieved on: 
Friday, November 3, 2023
Post-traumatic stress disorder, Knowledge, Ketamine, Policy, Roger Hawkins (drummer), CRNA, PMH, DSM-IV codes, Person, APNA, Bipolar disorder, American Psychiatric Nurses Association, Doctor of Philosophy, Multimedia, Environment, DNP, FAAN, AANA, Certified Registered Nurse Anesthetist, Crna, Nursing, Patient, Diagnosis, Anesthesia, Communication, Mental health, Pharmaceutical industry

Together, AANA and APNA have issued the following statement regarding ketamine infusion therapy for psychiatric disorders:

Key Points: 
  • Together, AANA and APNA have issued the following statement regarding ketamine infusion therapy for psychiatric disorders:
    "The AANA and APNA recognize the expertise of certified registered nurse anesthetists (CRNAs), psychiatric-mental health registered nurses (PMH RNs), and psychiatric-mental health advanced registered nurses (PMH APRNs) who are educated and qualified to administer ketamine infusion therapy for psychiatric disorders in accordance with professional scope and standards of practice, federal and state law, and facility policy."
  • When administering ketamine for treatment of psychiatric disorders, CRNAs collaborate with psychiatric-mental health professionals whose practice includes diagnosing psychiatric disorders within their professional and state scope of practice.
  • As part of the collaboration, CRNAs obtain a referral or past medical records, including a psychiatric history, medication list, and diagnosis, prior to providing ketamine infusion therapy for psychiatric disorders.
  • This expertise makes them an ideal partner in the delivery of ketamine infusion therapy for psychiatric disorders," said AANA President Dru Riddle, PhD, DNP, CRNA, FAAN.

North American Partners in Anesthesia Selects Cedar to Streamline the Patient Financial Experience

Retrieved on: 
Wednesday, November 1, 2023
Patient satisfaction, EVP, Pain management, Patient, NAPA, Nursing, Health insurance, Cedar, Anesthesia

NEW YORK and MELVILLE, N.Y., Nov. 1, 2023 /PRNewswire/ -- North American Partners in Anesthesia (NAPA), announced today that it has partnered with Cedar, an end-to-end healthcare financial engagement platform, to optimize the patient financial experience. As the largest single-specialty anesthesia and pain management company in the U.S., NAPA partners with nearly 400 healthcare facilities across 22 states. Cedar will power the post-visit billing experience for the more than two million patients who receive care annually from a NAPA clinician.

Key Points: 
  • Implementation of Cedar Pay for the largest single-specialty anesthesia and pain management company will improve patient satisfaction, drive digital engagement, and increase patient payments
    NEW YORK and MELVILLE, N.Y., Nov. 1, 2023 /PRNewswire/ -- North American Partners in Anesthesia (NAPA), announced today that it has partnered with Cedar , an end-to-end healthcare financial engagement platform, to optimize the patient financial experience.
  • Cedar will power the post-visit billing experience for the more than two million patients who receive care annually from a NAPA clinician.
  • Cedar Pay , Cedar's post-visit patient engagement and payment platform, helps providers increase patient payments and drive digital engagement—all while improving patient satisfaction—by applying a modern, consumer-obsessed approach.
  • "At Cedar, we know that when the billing experience is clear and easy to understand, patients are happier—and providers see better financial results.